tetano
Editor, Senior Moderator
J Med Invest
. 2022;69(1.2):148-151.
doi: 10.2152/jmi.69.148.
Retroperitoneal hemorrhage in a patient with coronavirus disease 2019 (COVID-19):A case report
Takuya Yoshioka[SUP] 1 [/SUP], Kei Daizumoto[SUP] 1 [/SUP], Kouki Tada[SUP] 1 [/SUP], Masato Mima[SUP] 2 [/SUP], Kozo Kagawa[SUP] 2 [/SUP], Tomoya Fukawa[SUP] 1 [/SUP], Kunihisa Yamaguchi[SUP] 1 [/SUP], Masayuki Takahashi[SUP] 1 [/SUP], Yasuhiko Nishioka[SUP] 2 [/SUP], Hiroomi Kanayama[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: Early prophylactic administration of anticoagulants is recommended in patients with coronavirus disease 2019 (COVID-19). A case of retroperitoneal hemorrhage during inpatient treatment for COVID-19 is reported.
Case presentation: A 69-year-old man was diagnosed with COVID-19 6 days after symptom onset. After admission for difficulty of breathing, he was treated with steroid pulse therapy, remdesivir, and heparin sodium. On day 16 after admission, his hemoglobin and blood pressure dropped. Computed tomography showed a left retroperitoneal hematoma and multiple areas of extravasation in bilateral iliopsoas muscles. Anticoagulation therapy was stopped, and blood transfusion therapy was chosen by considering poor general condition caused by severe pneumonia. On day 19, the hemoglobin and blood pressure improved, and blood transfusion was stopped. However, he died on day 25 due to pneumonia.
Conclusion: When retroperitoneal hemorrhage occurs as a complication of COVID-19, appropriate treatment decision, transcatheter arterial embolization or conservative treatment, should be chosen based on patient's condition. J. Med. Invest. 69 : 148-151, February, 2022.
Keywords: COVID-19; TAE; anticoagulants; nafamostat; retroperitoneal hemorrhage.
. 2022;69(1.2):148-151.
doi: 10.2152/jmi.69.148.
Retroperitoneal hemorrhage in a patient with coronavirus disease 2019 (COVID-19):A case report
Takuya Yoshioka[SUP] 1 [/SUP], Kei Daizumoto[SUP] 1 [/SUP], Kouki Tada[SUP] 1 [/SUP], Masato Mima[SUP] 2 [/SUP], Kozo Kagawa[SUP] 2 [/SUP], Tomoya Fukawa[SUP] 1 [/SUP], Kunihisa Yamaguchi[SUP] 1 [/SUP], Masayuki Takahashi[SUP] 1 [/SUP], Yasuhiko Nishioka[SUP] 2 [/SUP], Hiroomi Kanayama[SUP] 1 [/SUP]
Affiliations
- PMID: 35466138
- DOI: 10.2152/jmi.69.148
Abstract
Introduction: Early prophylactic administration of anticoagulants is recommended in patients with coronavirus disease 2019 (COVID-19). A case of retroperitoneal hemorrhage during inpatient treatment for COVID-19 is reported.
Case presentation: A 69-year-old man was diagnosed with COVID-19 6 days after symptom onset. After admission for difficulty of breathing, he was treated with steroid pulse therapy, remdesivir, and heparin sodium. On day 16 after admission, his hemoglobin and blood pressure dropped. Computed tomography showed a left retroperitoneal hematoma and multiple areas of extravasation in bilateral iliopsoas muscles. Anticoagulation therapy was stopped, and blood transfusion therapy was chosen by considering poor general condition caused by severe pneumonia. On day 19, the hemoglobin and blood pressure improved, and blood transfusion was stopped. However, he died on day 25 due to pneumonia.
Conclusion: When retroperitoneal hemorrhage occurs as a complication of COVID-19, appropriate treatment decision, transcatheter arterial embolization or conservative treatment, should be chosen based on patient's condition. J. Med. Invest. 69 : 148-151, February, 2022.
Keywords: COVID-19; TAE; anticoagulants; nafamostat; retroperitoneal hemorrhage.